Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy

BACKGROUND: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiseki, Masayuki, Yoshida, Chikashi, Takezako, Naoki, Ohwada, Akira, Kumagai, Takashi, Nishiwaki, Kaichi, Horikoshi, Akira, Fukuda, Tetsuya, Takano, Hina, Kouzai, Yasuji, Tanaka, Junji, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi, Inokuchi, Koiti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608785/
https://www.ncbi.nlm.nih.gov/pubmed/28550414
http://dx.doi.org/10.1007/s10147-017-1141-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608785/
https://www.ncbi.nlm.nih.gov/pubmed/28550414
http://dx.doi.org/10.1007/s10147-017-1141-y

Ejemplares similares